Immune Pharma names Paul Nadler CMO
This article was originally published in Scrip
Executive Summary
Immune Pharmaceuticals has appointed Dr Paul Nadler acting executive vice-president of R&D, and chief medical officer. In this position, Dr Nadler will be responsible for overseeing the development of Immune's immunology and oncology pipeline. Dr Nadler has been an interim or acting CMO (or similar) for a variety of early stage biotechnology companies such as OSI Pharmaceuticals, Fast Track Systems, Alexion Pharmaceuticals, CGI Pharma, Phylogix, Aveo, Dicerna and others.